Stephens Investment Management Group LLC Raises Holdings in Repligen Co. (NASDAQ:RGEN)

Stephens Investment Management Group LLC increased its position in Repligen Co. (NASDAQ:RGEN) by 7.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 536,801 shares of the biotechnology company’s stock after purchasing an additional 37,057 shares during the period. Repligen accounts for 1.0% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 28th largest holding. Stephens Investment Management Group LLC’s holdings in Repligen were worth $77,267,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Repligen by 46.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,629 shares of the biotechnology company’s stock worth $2,679,000 after purchasing an additional 5,913 shares during the last quarter. Alliance Wealth Advisors LLC UT grew its stake in shares of Repligen by 5.9% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 3,586 shares of the biotechnology company’s stock worth $516,000 after buying an additional 199 shares in the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of Repligen by 0.7% in the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after buying an additional 6,872 shares during the last quarter. Slow Capital Inc. raised its position in shares of Repligen by 3.3% during the 4th quarter. Slow Capital Inc. now owns 16,760 shares of the biotechnology company’s stock valued at $2,412,000 after buying an additional 534 shares in the last quarter. Finally, Ballentine Partners LLC raised its position in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 72 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $156.05 on Friday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm’s 50 day simple moving average is $155.37 and its 200-day simple moving average is $148.69. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the company posted $0.23 EPS. Repligen’s revenue was up 9.7% on a year-over-year basis. Analysts forecast that Repligen Co. will post 1.54 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on RGEN. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. HC Wainwright decreased their price target on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $184.73.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.